NO841230L - Interferon og interferon-induserende forbindelser kombinert med tobakksprodukter - Google Patents
Interferon og interferon-induserende forbindelser kombinert med tobakksprodukterInfo
- Publication number
- NO841230L NO841230L NO841230A NO841230A NO841230L NO 841230 L NO841230 L NO 841230L NO 841230 A NO841230 A NO 841230A NO 841230 A NO841230 A NO 841230A NO 841230 L NO841230 L NO 841230L
- Authority
- NO
- Norway
- Prior art keywords
- interferon
- product
- cells
- cigarette
- cigarettes
- Prior art date
Links
- 108010050904 Interferons Proteins 0.000 title claims description 241
- 102000014150 Interferons Human genes 0.000 title claims description 234
- 229940079322 interferon Drugs 0.000 title claims description 215
- 235000019505 tobacco product Nutrition 0.000 title claims description 9
- 150000001875 compounds Chemical class 0.000 title description 13
- 235000019504 cigarettes Nutrition 0.000 claims description 79
- 238000000034 method Methods 0.000 claims description 54
- 239000000126 substance Substances 0.000 claims description 32
- 239000012634 fragment Substances 0.000 claims description 13
- 230000008569 process Effects 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 230000006641 stabilisation Effects 0.000 claims description 7
- 238000011105 stabilization Methods 0.000 claims description 7
- 241000208125 Nicotiana Species 0.000 claims description 6
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims description 6
- 235000019506 cigar Nutrition 0.000 claims description 5
- 102000018832 Cytochromes Human genes 0.000 claims description 4
- 108010052832 Cytochromes Proteins 0.000 claims description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 3
- 108010071390 Serum Albumin Proteins 0.000 claims description 3
- 102000007562 Serum Albumin Human genes 0.000 claims description 3
- 229920001577 copolymer Polymers 0.000 claims description 3
- 229920000447 polyanionic polymer Polymers 0.000 claims description 3
- 102000008072 Lymphokines Human genes 0.000 claims 2
- 108010074338 Lymphokines Proteins 0.000 claims 2
- 210000004027 cell Anatomy 0.000 description 51
- 239000000779 smoke Substances 0.000 description 35
- 239000002245 particle Substances 0.000 description 28
- 230000000694 effects Effects 0.000 description 25
- 206010028980 Neoplasm Diseases 0.000 description 23
- 108090000623 proteins and genes Proteins 0.000 description 20
- 201000011510 cancer Diseases 0.000 description 19
- 230000001965 increasing effect Effects 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 17
- 229940047124 interferons Drugs 0.000 description 16
- 230000000391 smoking effect Effects 0.000 description 16
- 230000004071 biological effect Effects 0.000 description 15
- 230000001939 inductive effect Effects 0.000 description 13
- 210000004072 lung Anatomy 0.000 description 13
- 239000003814 drug Substances 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 150000001413 amino acids Chemical group 0.000 description 10
- 241000700605 Viruses Species 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 230000000840 anti-viral effect Effects 0.000 description 8
- 235000002639 sodium chloride Nutrition 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 230000009286 beneficial effect Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 108010088751 Albumins Proteins 0.000 description 6
- 102000009027 Albumins Human genes 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 108020004511 Recombinant DNA Proteins 0.000 description 6
- 230000000711 cancerogenic effect Effects 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 230000009931 harmful effect Effects 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 210000000214 mouth Anatomy 0.000 description 6
- 230000002195 synergetic effect Effects 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 230000008512 biological response Effects 0.000 description 5
- 229920002301 cellulose acetate Polymers 0.000 description 5
- 230000007547 defect Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 210000005260 human cell Anatomy 0.000 description 5
- 230000002209 hydrophobic effect Effects 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000000241 respiratory effect Effects 0.000 description 5
- 230000000087 stabilizing effect Effects 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 206010014561 Emphysema Diseases 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000012190 activator Substances 0.000 description 4
- 230000031018 biological processes and functions Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 231100000315 carcinogenic Toxicity 0.000 description 4
- 230000001066 destructive effect Effects 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 230000003211 malignant effect Effects 0.000 description 4
- 230000035800 maturation Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000011045 prefiltration Methods 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 206010006458 Bronchitis chronic Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 206010006451 bronchitis Diseases 0.000 description 3
- 231100000357 carcinogen Toxicity 0.000 description 3
- 239000003183 carcinogenic agent Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 208000007451 chronic bronchitis Diseases 0.000 description 3
- 230000007123 defense Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 229920002477 rna polymer Polymers 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 239000001488 sodium phosphate Substances 0.000 description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- FMMWHPNWAFZXNH-UHFFFAOYSA-N Benz[a]pyrene Chemical compound C1=C2C3=CC=CC=C3C=C(C=C3)C2=C2C3=CC=CC2=C1 FMMWHPNWAFZXNH-UHFFFAOYSA-N 0.000 description 2
- 101100148606 Caenorhabditis elegans pst-1 gene Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- 101001054334 Homo sapiens Interferon beta Proteins 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 239000003344 environmental pollutant Substances 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000037451 immune surveillance Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 210000001331 nose Anatomy 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- CKTSBUTUHBMZGZ-ULQXZJNLSA-N 4-amino-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-tritiopyrimidin-2-one Chemical compound O=C1N=C(N)C([3H])=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-ULQXZJNLSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
- 108010058683 Immobilized Proteins Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002942 anti-growth Effects 0.000 description 1
- 230000001064 anti-interferon Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003256 environmental substance Substances 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 239000012051 hydrophobic carrier Substances 0.000 description 1
- 230000002977 hyperthermial effect Effects 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000002799 interferon inducing agent Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000001483 mobilizing effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- -1 polypropylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- ONSIBMFFLJKTPT-UHFFFAOYSA-L zinc;2,3,4,5,6-pentachlorobenzenethiolate Chemical group [Zn+2].[S-]C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl.[S-]C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl ONSIBMFFLJKTPT-UHFFFAOYSA-L 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/18—Treatment of tobacco products or tobacco substitutes
- A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
- A24B15/30—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24D—CIGARS; CIGARETTES; TOBACCO SMOKE FILTERS; MOUTHPIECES FOR CIGARS OR CIGARETTES; MANUFACTURE OF TOBACCO SMOKE FILTERS OR MOUTHPIECES
- A24D1/00—Cigars; Cigarettes
- A24D1/18—Selection of materials, other than tobacco, suitable for smoking
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24D—CIGARS; CIGARETTES; TOBACCO SMOKE FILTERS; MOUTHPIECES FOR CIGARS OR CIGARETTES; MANUFACTURE OF TOBACCO SMOKE FILTERS OR MOUTHPIECES
- A24D3/00—Tobacco smoke filters, e.g. filter-tips, filtering inserts; Filters specially adapted for simulated smoking devices; Mouthpieces for cigars or cigarettes
- A24D3/06—Use of materials for tobacco smoke filters
- A24D3/14—Use of materials for tobacco smoke filters of organic materials as additive
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Materials Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Manufacture Of Tobacco Products (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/386,447 US4498485A (en) | 1982-08-05 | 1982-08-05 | Interferon and interferon inducers combined with tobacco products |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO841230L true NO841230L (no) | 1984-03-28 |
Family
ID=23525614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO841230A NO841230L (no) | 1982-08-05 | 1984-03-28 | Interferon og interferon-induserende forbindelser kombinert med tobakksprodukter |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US4498485A (fi) |
| EP (1) | EP0116085B1 (fi) |
| JP (1) | JPS59501496A (fi) |
| AT (1) | ATE28393T1 (fi) |
| AU (1) | AU561750B2 (fi) |
| DE (1) | DE3372568D1 (fi) |
| DK (1) | DK161738C (fi) |
| FI (1) | FI76246C (fi) |
| IT (1) | IT1168956B (fi) |
| NO (1) | NO841230L (fi) |
| WO (1) | WO1984000477A1 (fi) |
| ZA (1) | ZA835726B (fi) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5394869A (en) * | 1990-11-23 | 1995-03-07 | Covarrubias; Jesus | Method of inhibiting bronchospasms using taurine in an air filter |
| FR2696080B1 (fr) * | 1992-09-30 | 1994-12-23 | Jesus Covarrubias | Filtre à cigarette pour l'administration de taurine par inhalation. |
| GB2332359B (en) * | 1997-12-22 | 2001-10-24 | Richard Graham Kendall | Administration of a vitamin preparation to smokers via the filter tip of a cigarette |
| FR2798302B1 (fr) * | 1999-09-13 | 2001-12-21 | Frederic Maillard | Filtre compose d'heterocycles azotes tels que l'adn destine notamment a la filtration de fumee de tabac, cigarette comportant un tel filtre |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2890973A (en) * | 1954-03-03 | 1959-06-16 | Fachini Giuseppe | Treating tobacco and cigarette paper |
| US3339558A (en) * | 1966-10-28 | 1967-09-05 | Haskett Barry F | Smoking article and filter therefor containing vitamin a |
| US3667478A (en) * | 1969-07-17 | 1972-06-06 | Nelson J Waterbury | Filter cigarette incorporating vitamin a |
| EP0003064A3 (en) * | 1977-12-07 | 1979-08-08 | Rabam Limited | Method for introducing analogs of vitamin a into the respiratory tract of a cigarette smoker |
| JPS5579319A (en) * | 1978-12-07 | 1980-06-14 | Shiyaaman Baaton | Method of introducing vitamine a analogue to respiratory tract of smoker |
-
1982
- 1982-08-05 US US06/386,447 patent/US4498485A/en not_active Expired - Lifetime
-
1983
- 1983-08-04 AU AU18858/83A patent/AU561750B2/en not_active Ceased
- 1983-08-04 WO PCT/US1983/001199 patent/WO1984000477A1/en active IP Right Grant
- 1983-08-04 ZA ZA835726A patent/ZA835726B/xx unknown
- 1983-08-04 AT AT83902734T patent/ATE28393T1/de not_active IP Right Cessation
- 1983-08-04 JP JP83502817A patent/JPS59501496A/ja active Granted
- 1983-08-04 DE DE8383902734T patent/DE3372568D1/de not_active Expired
- 1983-08-04 EP EP83902734A patent/EP0116085B1/en not_active Expired
- 1983-08-05 IT IT22461/83A patent/IT1168956B/it active
-
1984
- 1984-03-28 NO NO841230A patent/NO841230L/no unknown
- 1984-04-02 FI FI841308A patent/FI76246C/fi not_active IP Right Cessation
- 1984-04-05 DK DK179384A patent/DK161738C/da not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP0116085B1 (en) | 1987-07-22 |
| DE3372568D1 (en) | 1987-08-27 |
| DK179384A (da) | 1984-04-05 |
| AU1885883A (en) | 1984-02-23 |
| EP0116085A1 (en) | 1984-08-22 |
| JPH0543347B2 (fi) | 1993-07-01 |
| AU561750B2 (en) | 1987-05-14 |
| FI76246B (fi) | 1988-06-30 |
| JPS59501496A (ja) | 1984-08-23 |
| EP0116085A4 (en) | 1984-11-16 |
| US4498485A (en) | 1985-02-12 |
| DK179384D0 (da) | 1984-04-05 |
| ATE28393T1 (de) | 1987-08-15 |
| IT1168956B (it) | 1987-05-20 |
| DK161738C (da) | 1992-02-24 |
| DK161738B (da) | 1991-08-12 |
| FI841308A0 (fi) | 1984-04-02 |
| FI76246C (fi) | 1988-10-10 |
| IT8322461A0 (it) | 1983-08-05 |
| FI841308A (fi) | 1984-04-02 |
| WO1984000477A1 (en) | 1984-02-16 |
| ZA835726B (en) | 1984-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Redwan et al. | Potential lactoferrin activity against pathogenic viruses | |
| Foster et al. | Are all type I human interferons equivalent? | |
| Stafford et al. | Products of proteolytic cleavage of transferrin induce nitric oxide response of goldfish macrophages | |
| Agraz-Cibrian et al. | Understanding the molecular mechanisms of NETs and their role in antiviral innate immunity | |
| TWI375716B (en) | Recombinant human interferon-like proteins | |
| JP2012529440A (ja) | 病原体感染を予防又は治療するためのインターフェロン投与 | |
| SG191287A1 (en) | Antimicrobial fusion compounds and uses thereof | |
| Emanuelli et al. | The integrated stress response in pulmonary disease | |
| JP2020519673A5 (fi) | ||
| Cheng et al. | Vitamin D3 modulates yellow catfish (Pelteobagrus fulvidraco) immune function in vivo and in vitro and this involves the vitamin D3/VDR-type I interferon axis | |
| Al-Momani et al. | Effect of different heavy-metal concentrations on Drosophila melanogaster larval growth and development | |
| Naito et al. | Therapeutic potential of carbon monoxide (CO) for intestinal inflammation | |
| Sheshe et al. | Mechanism of antiviral immune response and COVID-19 infection | |
| NO841230L (no) | Interferon og interferon-induserende forbindelser kombinert med tobakksprodukter | |
| Deng et al. | First in vitro and in vivo evaluation of recombinant IL-1β protein as a potential immunomodulator against viral infection in fish | |
| CN105496972A (zh) | 一种鸡干扰素冻干剂的制备方法 | |
| AU561752B2 (en) | Broad spectrum plant protection from pathogens | |
| NO173144B (no) | Fremgangsmaate til fremstilling av interferongamma | |
| RU2526799C2 (ru) | Фармацевтическая композиция и способ получения противовирусных фракций (антивирус-с) | |
| Wen et al. | Current progress on innate immune evasion mediated by Npro protein of pestiviruses | |
| Purbomartono et al. | Non Specific Immune Potentiating Evaluation of Brown Seaweed of Padina sp. in Catfish and Pangasius | |
| RU2380405C2 (ru) | Способ получения рекомбинантного альфа 16-интерферона человека и фармацевтическая композиция для лечения вирусных заболеваний на основе рекомбинантного альфа 16-интерферона человека | |
| Polcyn-Adamczak et al. | Cathelicidin–Its Structure, Function and the Role in Autoimmune Diseases | |
| Daino | Characterization of Ebola virus VP35-dsRNA binding for drug development against Ebola virus disease. | |
| Chen et al. | Sea perch (Lateolabrax japonicus) UBC9 augments RGNNV infection by hindering RLRs-interferon response |